Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 April 2021 | Story NONSINDISO QWABE | Photo Thabo Kessah
Faith Mudzingiri.

Sharing her father’s love for the field of commerce, Faith Mudzingiri, daughter of Dr Calvin Mudzingiri, Assistant Dean of the Faculty of Economic and Management Sciences, is one of the more than 1 500 students who received their qualifications during the University of the Free State Qwaqwa Campus virtual graduation ceremony. Faith obtained her BCom General Management degree during the virtual ceremony on 21 April.

In 2020, Mudzingiri topped the academic charts as the best student across all faculties on the campus.

Following in the footsteps of her father

An accounting enthusiast from an early age, Faith said her father has been her biggest motivation. Having a parent in such a critical position can come with immense pressure to perform, but she said “watching him inspired me a lot. For me to be here, is because I’ve learned from him that hard work pays off”.

Mudzingiri said while she was grateful for the accomplishment of being the Dux student for 2020, her academics did not get off to a good start in 2017 when she began her first year.

“As an international student coming from Zimbabwe, I struggled a lot in my first year. I had difficulty finding my feet in the new environment. Things got better in my second year, but in my third year I reminded myself why I was here and why I started this degree. I knew I wanted to graduate in record time, and so had to put in the work.”

Still set on achieving her accounting dream, Mudzingiri is now pursuing a BCom Accounting degree on the Bloemfontein Campus. “I would love to become a tax accountant and start my own accounting firm one day.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept